Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.55 |
| ▸ | ABAT | P80404 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337112 | 0.93 | ALDH1A1 (0.60) | ALDH1A1ALDH5A1ABATPARP10PARP3 | |
| SCHEMBL28271046 | 0.91 | CES2 (0.68) | ALDH1A1ALDH5A1ABATPARP10PARP3 | |
| SCHEMBL6852409 | 0.83 | ALDH1A1 (0.68) | ALDH1A1ALDH5A1ABATPARP10PARP3 | |
| Benzil SCHEMBL7790900 | 0.82 | CES2 (0.67) | ALDH1A1CES2CES1CYP2A6 | |
| SCHEMBL12344141 | 0.82 | ALDH1A1 (0.54) | ALDH1A1ALDH5A1ABATPARP10PARP3 | |
| Terephthalic Acid SCHEMBL11068404 | 0.81 | ALDH1A1 (1.00) | ALDH1A1ALDH5A1ABATPARP10PARP3 | |
| SCHEMBL1664743 | 0.81 | ALDH1A1 (0.65) | ALDH1A1ALDH5A1ABATPARP10PARP3 | |
| SCHEMBL18133156 | 0.81 | ALDH1A1 (0.65) | ALDH1A1ALDH5A1ABATPARP10PARP3 | |
| SCHEMBL63361 | 0.81 | ALDH1A1 (1.00) | ALDH1A1ALDH5A1ABATPARP10PARP3 | |
| SCHEMBL28435221 | 0.80 | ALDH1A1 (0.66) | ALDH1A1ALDH5A1ABATPARP10PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842830-B2 | Transition-metal charge-transport materials, methods of fabrication thereof, and methods of use thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080121870-A1 | Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof | GEORGIA TECH RESEACH CORPORATION | 2008-05-29 | — | — | US | disclosed |
| WO-2005123754-A2 | TRANSITION-METAL CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080121870-A1 | Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof | SLC39A3, SLC6A6, SLC6A9 | ALDH1A1 2421/4885ALDH5A1 2201/4885ABAT 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.